June 2013
Volume 54, Issue 15
Free
ARVO Annual Meeting Abstract  |   June 2013
A Mechanism-Based Binding Model for the Pharmacokinetics and Pharmacodynamics (PK-PD) of RN6G (PF-04382923), a Humanized Monoclonal Antibody against Amyloid β Peptides, in Subjects with Dry, Age-Related Macular Degeneration Including Geographic Atrophy
Author Affiliations & Notes
  • Kai Liao
    Pfizer Inc, San Diego, CA
  • Pamela Garzone
    Pfizer Inc, South San Francisco, CA
  • Sangeetha Bollini
    Pfizer Inc, South San Francisco, CA
  • Philip Fanning
    Pfizer Inc, South San Francisco, CA
  • Gilbert Wong
    Pfizer Inc, South San Francisco, CA
  • Xu Meng
    Pfizer Inc, San Diego, CA
  • Footnotes
    Commercial Relationships Kai Liao, Pfizer Inc (E); Pamela Garzone, Pfizer (E); Sangeetha Bollini, Pfizer (E); Philip Fanning, Pfizer (E); Gilbert Wong, Pfizer, Inc (E); Xu Meng, Pfizer Inc (E)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2013, Vol.54, 3287. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Kai Liao, Pamela Garzone, Sangeetha Bollini, Philip Fanning, Gilbert Wong, Xu Meng; A Mechanism-Based Binding Model for the Pharmacokinetics and Pharmacodynamics (PK-PD) of RN6G (PF-04382923), a Humanized Monoclonal Antibody against Amyloid β Peptides, in Subjects with Dry, Age-Related Macular Degeneration Including Geographic Atrophy. Invest. Ophthalmol. Vis. Sci. 2013;54(15):3287.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract
 
Purpose
 

RN6G (PF-04382923) is a humanized IgG2Δa monoclonal antibody that binds with high affinity to amyloid β (Aβ) peptides Aβ1-40 and Aβ1-42 at the free C-terminal region. It is under development as treatment for patients with geographic atrophy (GA) related to dry age-related macular degeneration (ARMD). Data from a single ascending dose (SAD) and emerging data from a multiple ascending dose (MAD) study in subjects with dry ARMD showed distinctive RN6G PK profiles characterized by a dose-dependent distribution phase, which cannot be fully explained by the observed PD (Aβ) concentration profiles in plasma. The objective of this analysis was to develop and evaluate a mechanism-based predictive population PK-PD model that describes the data from these Phase I studies in subjects with early and with advanced dry ARMD.

 
Methods
 

The database included 714 RN6G and 1178 Aβ1-x (n=864 from Gyros assay, n=314 from liquid chromatography-tandem mass spectrometry) samples from the Phase I studies (B1181001 and B1181002). These data were simultaneously analyzed via nonlinear mixed-effects modeling with NONMEM, v 7.1.2.

 
Results
 

The time course of RN6G and its interplay with Aβ1-x were delineated in the mechanism-based PK-PD model. By incorporating an Aβ1-x-rich compartment, the model was able to adequately describe the dose-dependent distribution phase of RN6G, as well as the Aβ1-x profiles observed in plasma. The initial model from the SAD study was used to select the dosage regimen for the MAD study. The preliminary PK/PD data from the MAD study provided verification of the predictions by the model, which was then used for the dose regimen selection for the proof-of-concept study. Simulation results suggest that the level of sequestration for free Aβ in plasma might not be indicative of that in tissues with higher Aβ1-x concentration such as choroid or vitreous humour.

 
Conclusions
 

A mechanism-based binding model was developed to adequately describe the distinctive disposition profiles of RN6G and the observed Aβ1-x concentration profiles in plasma. This modeling work provided the rationale for dosage regimens for RN6G early clinical trials.

 
Keywords: 412 age-related macular degeneration  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×